Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1460457
European Journal of Endocrinology, Vol 146, Issue 4, 457-461
Copyright © 2002 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bartalena, L
Right arrow Articles by Pinchera, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bartalena, L
Right arrow Articles by Pinchera, A

Articles

Graves' ophthalmopathy: a preventable disease?

L Bartalena, C Marcocci, and A Pinchera

Cattedra di Endocrinologia, University of Insubria, Varese, Italy. l.bartalena@libero.it

Most patients with Graves' disease have some degree of ocular involvement, but only 3-5% of them develop severe ophthalmopathy (1). The reasons why only such a minority of patients with Graves' disease have severe expression of the ophthalmopathy remain to be elucidated. One possible explanation is that non-severe ophthalmopathy and severe ophthalmopathy are two different disorders with different genetic backgrounds; alternatively, they might be part of a spectrum of different conditions ranging from absent ocular involvement to most severe ophthalmopathy. In this case, external variables (i.e. environmental factors) must contribute to the nature of the expression of the disease. How important are they? How far can our intervention on environmental factors go towards reducing the risk of progression of the ophthalmopathy? In other words, to which extent, if any, is Graves' ophthalmopathy preventable? The aim of this mini-review is to address the above issues.


This article has been cited by other articles:


Home page
IOVSHome page
K. K. L. Chong, S. W. Y. Chiang, G. W. K. Wong, P. O. S. Tam, T.-K. Ng, Y.-J. Hu, G. H. F. Yam, D. S. C. Lam, and C.-P. Pang
Association of CTLA-4 and IL-13 Gene Polymorphisms with Graves' Disease and Ophthalmopathy in Chinese Children
Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2409 - 2415.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al.
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
L D K E Premawardhana and J H Lazarus
Management of thyroid disorders.
Postgrad. Med. J., September 1, 2006; 82(971): 552 - 558.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. E. Feldon, D. J. J. Park, C. W. O'Loughlin, V. T. Nguyen, S. Landskroner-Eiger, D. Chang, T. H. Thatcher, and R. P. Phipps
Autologous T-Lymphocytes Stimulate Proliferation of Orbital Fibroblasts Derived from Patients with Graves' Ophthalmopathy
Invest. Ophthalmol. Vis. Sci., November 1, 2005; 46(11): 3913 - 3921.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Bartalena, C. Marcocci, and A. Pinchera
Somatostatin Analogs for Graves' Ophthalmopathy: Do They Bounce Off like a Rubber Bullet?
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5908 - 5909.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Bartalena, C. Marcocci, and A. Pinchera
Orbital Radiotherapy for Graves' Ophthalmopathy
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 13 - 14.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 European Society of Endocrinology.